Article

Potential Benefit of Early Treatment with Sotrovimab in Patients With High Risk for Severe COVID-19 Carrying BA.2 Infection

2022-07-14

Abstract excerpt

Coronavirus disease 19 (COVID-19) continues to spread worldwide as a severe pandemic. The Omicron BA.2 became the predominant variant and the protagonist of the ongoing surge. As the virus continues to mutate, using of approved drugs or developing new therapeutic or prophylactic therapies against COVID-19 could be more complex. Sotrovimab is a monoclonal antibody (mAb) targeting the conserved epitope on the spike...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a3d16f25-5958-5884-ac17-47f4645933c7
DOI: 10.20944/preprints202207.0223.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Potential Benefit of Early Treatment with Sotrovimab in Patients With High Risk for Severe COVID-19 Carrying BA.2 InfectionDOI 10.20944/preprints202207.0223.v1Read

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 VariantsSemantic proximity Read

High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variantSemantic proximity Read

Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature reviewSemantic proximity Read

Characteristics and Outcomes of COVID-19 Patients Presumed to be Treated with Sotrovimab in NHS Hospitals in EnglandSemantic proximity Read

Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patientsSemantic proximity Read

Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodiesSemantic proximity Read

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patientsSemantic proximity Read

Effectiveness of Sotrovimab in Preventing COVID-19-related Hospitalizations or Deaths Among U.S. VeteransSemantic proximity Read

Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients During the Omicron PhaseSemantic proximity Read

Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 OutpatientsSemantic proximity Read

In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5Semantic proximity Read

Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the United StatesSemantic proximity Read